uniQure N.V. (QURE) is in Healthcare, Biotechnology, based in Netherlands, listed on NasdaqGS. Market cap 1.56B USD. 52-week range 8.73 to 71.50 USD. Data as of 2026-10-09.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial ...